Back

Implementing empagliflozin for HFpEF treatment in my practice.

27 August 2022 (13:00 - 13:30)
Organised by:
Congress Presentation Part of: SGLT2 inhibitors in practice (part 2): how do we implement new treatments in HFpEF? Heart Failure with Preserved Ejection Fraction (HFpEF) Open Access ESC Congress 2022

About the speaker

Photo
Professor Michael Boehm

Saarland University Hospital, Homburg (Germany)

3 More presentations in this session

Presentation thumbnail
Introduction and recap.
Professor S. Anker (Berlin, DE)
Slides Video
Presentation thumbnail
What is the evidence for empagliflozin in HFpEF?
Professor G. Rosano (London, GB)
Slides Video
Presentation thumbnail
Panel discussion.
Professor S. Anker (Berlin, DE)
Slides Video

Access the full session

Session thumbnail
SGLT2 inhibitors in practice (part 2): how do we implement new treatments in HFpEF?
Video

The Event

Event poster

ESC Congress 2022

27 August 2022 13:00 CET
You may be interested in
thumbnail
Congress Presentation
SGLT2 inhibition in patients with HFpEF ‒ a case-based discussion.
23 May 2022
thumbnail
Congress Presentation
Using empagliflozin for HFpEF treatment - what does this look like in practice?
22 May 2022
thumbnail
Congress Presentation
Drug treatment of HFpEF: whom to treat and what works and what does not work
28 August 2022
thumbnail
Congress Session
SGLT-2 inhibitors - Another piece of the puzzle in heart failure
29 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources